Physician

Joyce Jiaying Huang, MD PHD

According to 2025 Medicare claims, Joyce Huang, MD PHD (NPI: 1285991638) practices internal medicine in the York-Hanover, PA market, with the plurality of this provider's patient population coming from York, PA. This provider's primary affiliated billing organization is CANCER CARE ASSOCIATES OF YORK, INC. (NPI: 1578587101; TIN: 232122436) and primary practice location at 17403-5049.

Huang's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 843 traditional Medicare patients, billed 183,259 HCPCS/CPT codes, and received $3,797,251 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,203 prescription claims across 290 beneficiaries totaling $948,860 in drug costs, led by Lenalidomide (Lenalidomide). 2022 DME data shows 15 claims. Open Payments data shows 20 records totaling $4,887. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $5,628 to $3,797,251. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,104 to $948,860. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	51	88	$5,628
2016	279	21,091	$302,555
2017	779	145,987	$1,713,829
2018	879	223,770	$2,840,550
2019	937	208,776	$2,669,713
2020	860	176,431	$2,476,555
2021	867	121,289	$2,429,174
2022	859	160,477	$2,964,519
2023	868	144,842	$2,874,933
2024	843	183,259	$3,797,251

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	25	47	$1,104
2016	58	137	$32,241
2017	118	404	$152,962
2018	204	710	$126,774
2019	218	672	$194,267
2020	184	703	$330,807
2021	192	763	$277,112
2022	201	873	$237,672
2023	242	1,047	$474,653
2024	290	1,203	$948,860

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	42	114	$20,279
2018	98	222	$13,092
2019	N/R	18	$5,269
2020	N/R	12	$1,696
2021	N/R	40	$3,651
2022	N/R	15	$1,192
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	249	441	$129
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	259	406	$12
80053	Blood test, comprehensive group of blood chemicals	301	733	$10
36415	Insertion of needle into vein for collection of blood sample	389	1,015	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	371	941	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	12	336	$188,767
Eliquis	Apixaban	98	4,742	$91,659
Xarelto	Rivaroxaban	16	660	$11,555
Letrozole	Letrozole	196	16,501	$3,848
Anastrozole	Anastrozole	146	11,753	$2,779

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	20	$4,887	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Joyce Jiaying Huang, MD PHD?

Tedicare shows public-source Medicare data for Joyce Jiaying Huang, MD PHD (NPI 1285991638), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Joyce Jiaying Huang, MD PHD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Joyce Jiaying Huang, MD PHD?

Joyce Jiaying Huang, MD PHD is linked to CANCER CARE ASSOCIATES OF YORK, INC. (billing NPI 1578587101) in the available physician profile data.

Does Joyce Jiaying Huang, MD PHD have Open Payments data?

Joyce Jiaying Huang, MD PHD has 20 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.